6690 related articles for article (PubMed ID: 2386979)
1. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2.
Eisenthal A
Cancer Immunol Immunother; 1990; 31(6):342-8. PubMed ID: 2386979
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
5. The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha.
Eisenthal A; Rosenberg SA
J Immunol; 1989 Apr; 142(7):2307-13. PubMed ID: 2647849
[TBL] [Abstract][Full Text] [Related]
6. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
Chao TY; Ohnishi H; Chu TM
Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
[TBL] [Abstract][Full Text] [Related]
8. Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin.
Kuppen PJ; Eggermont AM; Marinelli A; de Heer E; van de Velde CJ; Fleuren GJ
Cancer Immunol Immunother; 1991; 33(1):28-32. PubMed ID: 2021956
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
Pendurthi TK; Parker R; Schlom J; Primus FJ
Int J Cancer; 1990 Dec; 46(6):1021-8. PubMed ID: 2123477
[TBL] [Abstract][Full Text] [Related]
10. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Eisenthal A; Cameron RB; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
[TBL] [Abstract][Full Text] [Related]
11. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.
Gazit Z; Kedar E
Cancer Immunol Immunother; 1994 Apr; 38(4):243-52. PubMed ID: 8168119
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.
Kuroki Y; Ochiai H; Kurokawa M; Niwayama S; Kishimoto C; Tazawa K; Fujimaki M
J Cancer Res Clin Oncol; 1991; 117(2):109-14. PubMed ID: 2007609
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of murine lymphokine-activated killer (LAK) cell activity by adherent cells.
Longley RE; Stewart D; Roe KG; Good RA
Cell Immunol; 1989 Jul; 121(2):225-36. PubMed ID: 2786756
[TBL] [Abstract][Full Text] [Related]
15. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice.
Watanabe M; Kubota T; Kitajima M; Hakomori S
Cancer Immunol Immunother; 1993 Sep; 37(4):245-50. PubMed ID: 8348564
[TBL] [Abstract][Full Text] [Related]
16. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
17. Induction of endogenous lymphokine-activated killer activity by combined administration of lentinan and interleukin 2.
Suzuki M; Higuchi S; Taki Y; Taki S; Miwa K; Hamuro J
Int J Immunopharmacol; 1990; 12(6):613-23. PubMed ID: 2272726
[TBL] [Abstract][Full Text] [Related]
18. Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2.
Eisenthal A; Rosenberg SA
Cancer Res; 1989 Dec; 49(24 Pt 1):6953-9. PubMed ID: 2573425
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human tumor necrosis factor alpha on the induction of antibody-dependent cellular cytotoxicity in the treatment of established B16 melanoma liver nodules.
Eisenthal A; McIntosh JK
Cancer Immunol Immunother; 1990; 31(4):243-9. PubMed ID: 2379220
[TBL] [Abstract][Full Text] [Related]
20. The augmentation of lymphokine-activated killer cell activity by indomethacin in vitro is not mediated by prostaglandin E2 suppression.
Chao TY; Ting CS; Chu TM; Yeh MY
Proc Natl Sci Counc Repub China B; 1993 Oct; 17(4):138-42. PubMed ID: 8171164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]